Latest stories on NRIX
Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Seeking Alpha56 · neutralproduct/pr
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
StockTitan56 · neutralgeneral
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire56 · neutralgeneral
Nurix Advances NX-5948 Combo Trial in B-Cell Cancers, Setting Up Key Catalyst for NRIX
TipRanks63 · neutralproduct/pr
Nurix Therapeutics: Roche Has Changed The Economics Of The Bull Case
Seeking Alpha78 · bullishproduct/pr
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
Business Insider55 · neutralgeneral
Nurix Therapeutics, Inc. (NRIX) files 8-K
SEC 8-K50 · neutralgeneral
Nurix Therapeutics GAAP EPS of -$0.81 misses by $0.08, revenue of $9.04M misses by $6.25M
Seeking Alpha34 · bearishearnings
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | NRIX Stock News
StockTitan73 · bullishproduct/pr
Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value
Yahoo Top61 · neutralanalyst
Nurix (NRIX) Climbs to 52-Week High — This Deal May Hold the Answer
Yahoo Top73 · bullishproduct/pr
Truist is Bullish on Nurix Therapeutics, Inc. (NRIX)
Yahoo Top61 · neutralanalyst
Nurix Therapeutics Deal With Roche Is Worth Betting On
Seeking Alpha67 · bullishproduct/pr
Nurix Highlights Promising Phase 1b Data for Bexobrutideg
TipRanks67 · bullishproduct/pr
Nurix Therapeutics, Inc. (NRIX) files 8-K
SEC 8-K50 · neutralgeneral
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions
Seeking Alpha78 · bullishanalyst
Roche Licenses Nurix Therapeutics Blood-Cancer Drug for Up to $2.3 Billion — Update
Morningstar73 · bullishm&a
Roche enters cancer drug deal worth up to $2.3 billion with Nurix Therapeutics
Reuters67 · bullishm&a
This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug
Barron's73 · bullishm&a